A Phase III Study to Evaluate the Efficacy and Safety of AK120 in Patients With Moderate to Severe Atopic Dermatitis

Inclusion Criteria: 1. Male or female subjects aged ≥18≤75 years old. 2. Atopic dermatitis (AD) diagnosed at least 1 year before screening. 3. Subject with eczema area and severity index (EASI) score ≥16, Investigator Global Assessment (IGA) score≥ 3, Body Surface Area (BSA) score ≥ 10% at screening and baseline. 4. Previously received at least 4 weeks of moderate to strong or at least 2 weeks of strong local glucocorticoid (TCS) treatment for AD before screening, with poor efficacy or intolerable Exclusion Criteria: 1. Acute onset of AD within the first 4 weeks of randomization. 2. Have participated in any clinical research on AK120 in the past 3. Received systemic corticosteroids, immunosuppressive/immunomodulatory drugs, phototherapy within the 4 weeks before randomization. 4. Received treatment with other clinical research drugs (non-biological agents) within the first 4 weeks or 5 half-lives of randomization (whichever is longer) 5. Received or planned to receive live vaccine treatment within the 3 months before randomization or during the study period. 6. Received allergen specific immunotherapy within the 3 months before randomization. 7. Have a history of allergies to any component of AK120 and/or severe allergic reactions to monoclonal antibodies.